Cover Image

IntegrateALL: An end‐to‐end RNA‐seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B‐precursor ALL

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Nadine Wolgast, Thomas Beder, Mayukh Mondal, Wencke Walter, Stephan Hutter, Sonja Bendig, Jan Kässens, Björn‐Thore Hansen, Katharina Iben, Sebastian Wolf, Anjali Cremer, Malwine Barz, Martin Neumann, Nicola Gökbuget, Claudia Haferlach, Monika Brüggemann, Claudia D. Baldus, Alina M. Hartmann, Lorenz Bastian
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	HemaSphere
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Intra‐subtype heterogeneity shapes treatment response in KMT2A ‐rearranged ALL across all age groups
by: Alina M. Hartmann, et al.
Published: (2026)

Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
by: Roger Mulet‐Lazaro, et al.
Published: (2025)

Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy
by: Gunnar Cario, et al.
Published: (2025)

Biological and clinical characteristics of ETV6 :: RUNX1 ‐like ALL
by: Marketa Zaliova, et al.
Published: (2026)

Overcoming a T‐ALL order: A comprehensive study linking genomics to clinical outcomes
by: Yizhou Huang, et al.
Published: (2024)

Parents' perception of treatment‐related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia
by: Nina Mogensen, et al.
Published: (2024)

Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL
by: Jean‐Edouard Martin, et al.
Published: (2026)

The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
by: Anna Stengel, et al.
Published: (2026)

Correction to “Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes”
Published: (2024)

TWIST2 high expression defines a novel subtype of B‐cell precursor acute lymphoblastic leukemia
by: Tao Zeng, et al.
Published: (2026)

Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma
by: Xiang Zhou, et al.
Published: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
by: Jan‐Niklas Eckardt, et al.
Published: (2025)

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
by: Stella Charalampopoulou, et al.
Published: (2026)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
by: Harmony C. Ketchum, et al.
Published: (2025)

Thrombotic complications of central venous catheterization with peripherally inserted catheters in patients with classical‐Hodgkin lymphoma
by: Marco Picardi, et al.
Published: (2025)

Hematology in times of crisis: Lessons learned and strategic priorities from the EHA–ASH Joint Workshop on Ukraine
by: Oleksandr Istomin, et al.
Published: (2026)

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients
by: Caroline Diorio, et al.
Published: (2026)

Daratumumab‐based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case‐control study
by: Claudia Bellofiore, et al.
Published: (2025)

Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy)
by: Martijn P. T. Ernst, et al.
Published: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
by: Martijn W. C. Verbeek, et al.
Published: (2025)

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
by: Claudia Bellofiore, et al.
Published: (2026)

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
by: Frank G. Rücker, et al.
Published: (2024)

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
by: Anna Maria Frustaci, et al.
Published: (2025)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
by: Kazimierz Groen, et al.
Published: (2024)

Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
by: Kazimierz Groen, et al.
Published: (2025)

Clonal hematopoiesis dynamics influences long‐term outcomes of follicular lymphoma: Results from FIL FOLL12 trial
by: Nawar Maher, et al.
Published: (2026)

Issue Information
Published: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
by: Raúl Córdoba, et al.
Published: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
by: Anna Ossami Saidy, et al.
Published: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
by: Enrico Attardi, et al.
Published: (2024)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
by: Henri C. Hupe, et al.
Published: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
by: Konstanze Döhner, et al.
Published: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
by: Stephanie Sembill, et al.
Published: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
by: Uwe Platzbecker, et al.
Published: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
by: Sotiroula Chatzimatthaiou, et al.
Published: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
by: Elia Colin, et al.
Published: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Published: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
by: Daniel Mazza Matos
Published: (2026)

Publication Only
Published: (2025)